Figure 3.

Tipping point sensitivity analysis of the cost of duloxetine. The incremental cost-effectiveness ratios (ICERs) for depression screening and universal duloxetine are presented in relation to relative increases in the cost of an annual prescription of 60 mg of generic duloxetine. Solid lines represent base case toxicity values; dotted lines represent the increased toxicity parameters, which includes an increased risk of falls and sexual dysfunction. Red lines represent the $50,000 and $100,000/QALY willingness-to-pay thresholds.